Expert Interview
Advancing Lyme Disease Prevention: A Comprehensive Analysis of TP-05 and VLA15 in Prophylactic Strategies
Ticker(s): TARS, VALNInstitution: Penn Presbyterian Medical Center
- Associate Professor of Clinical Medicine (Infectious Diseases) and Medical Director, Infectious Diseases Transition Service at Penn Presbyterian Medical Center.
- Currently manages about 2-4 patients with Lyme Disease per week.
- Clinical expertise in HIV and AIDS, Lyme Disease, Osteomyelitis, Outpatient Antimicrobial Treatment (OPAT), STD's, Travel Medicine, and Tuberculosis (TB).
Can you discuss the significance of TP-05's tick mortality rates observed in the Carpo trial and its potential impact on Lyme disease prevention?
Added By: slingshot_insightsHow do the mechanisms of TP-05 and VLA15 differ in preventing Lyme disease, and what are the implications of these differences for their use in prophylaxis?
Added By: slingshot_insightsBased on the trial data, how do the safety profiles of TP-05 and VLA15 compare, and what does this mean for their potential widespread use?
Added By: slingshot_insightsHow does the efficacy of VLA15, as indicated by the seroconversion rates and GMTs post-booster dose, vary across different age groups?
Added By: slingshot_insightsCould combining TP-05's tick-killing action with VLA15's immunogenic response offer a more comprehensive approach to Lyme disease prevention
Added By: slingshot_insightsWhat can be inferred about the long-term protection prospects against Lyme disease with the use of TP-05 and VLA15, either separately or in combination?
Added By: slingshot_insightsHow do TP-05 and VLA15 compare with existing Lyme disease prevention strategies, particularly in terms of efficacy and ease of use?
Added By: slingshot_insightsWhat are the anticipated next steps in the clinical development of TP-05 and VLA15, and how might these developments alter the landscape of Lyme disease prevention?
Added By: slingshot_insightsHow concerning is the FDA warning about drugs in this class causing tremors in dogs and cats:
“Isoxazoline products have been associated with neurologic adverse reactions, including muscle tremors, ataxia, and seizures in some dogs and cats”
https://www.fda.gov/animal-veterinary/animal-health-literacy/fact-sheet-pet-owners-and-veterinarians-about-potential-adverse-events-associated-isoxazoline-flea
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
